Slingshot members are tracking this event:

Allergan's BOTOX Vista (botulinum toxin type A) Receives National Marketing Authorisation in Japan for Treatment of Crow's Feet Lines in Adult Patients

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
AGN Community voting in process

Additional Information

Additional Relevant Details New aesthetic indication in Japan for market-leading toxin demonstrates Allergan's long term commitment to innovation in medical aesthetics
Medical aesthetics is a fast growing healthcare sector in Japan, with a 56% rise in the number of surgical and non-surgical treatments performed from 2010 to 2014(1,2)

Japanese Ministry of Health, Labour and Welfare has approved an additional use for BOTOX Vista (Allergan's botulinum toxin type A product) as a treatment for crow's feet lines (CFL).3 BOTOX Vista is now indicated for the temporary improvement in the appearance of lateral canthal lines (CFL) in adult patients under the age of 65.
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 23, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Botulinum Toxin Type A, Botox Vista, Lateral Canthal Lines, Cfl